trending Market Intelligence /marketintelligence/en/news-insights/trending/EI9wGAeMyZC0QAey1boM5Q2 content esgSubNav
In This List

Teva seeks US FDA approval for migraine treatment

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Teva seeks US FDA approval for migraine treatment

Teva Pharmaceutical Industries Ltd. filed a biologics license application, seeking approval for its migraine treatment fremanezumab from the U.S. Food and Drug Administration.

The submission is supported by the results of two phase 3 trials that involved patients with episodic and chronic migraine. The drug met its primary and secondary endpoints reducing the number of migraine days.

Fremanezumab is a fully humanized monoclonal antibody targeting the calcitonin gene-related peptide ligand, a well-validated target in migraine.